+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are evaluating how well zenagamtide works and how safe it is compared to insulin glargine in people with type 2 diabetes who have a higher risk of heart and blood vessel problems. This study includes participants already taking 1 to 3 diabetes medications and aims to see if zenagamtide is not worse than insulin glargine in controlling blood sugar levels over one year. Participants are randomly assigned to receive either zenagamtide or insulin glargine. Zenagamtide is given once weekly as an injection under the skin in the thigh, abdomen, or upper arm using a pre-filled pen injector. Insulin glargine is given once daily as a subcutaneous injection in the same body areas, with rotation of the injection site. The study lasts for at least 52 weeks for primary outcomes, with cardiovascular events monitored for 104 weeks or more. During the study, participants will have regular assessments including blood tests for HbA1c, body weight measurements, waist circumference, blood pressure, cholesterol levels, and markers of inflammation. The main measure is the change in blood sugar control after 52 weeks. The study also tracks heart-related events and other health changes over two years. Participants will be monitored closely throughout the study period to evaluate safety and treatment effects.

Age: 45Years +All GendersPhase 3
330 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are studying the safety, dosing, and effectiveness of the drug GS-4321 in both healthy individuals and people with chronic hepatitis delta CHD. The study has two phases Phase 1 focuses on safety, tolerability, and drug levels in healthy participants, while Phase 2 evaluates safety and effectiveness in participants with CHD. The study aims to understand how GS-4321 works and its impact on this liver condition. Participants in Phase 1 receive single escalating doses of GS-4321 or placebo, administered either under the skin or intravenously, to assess dose safety and drug behavior. In Phase 2, participants with CHD receive multiple escalating doses of GS-4321 over up to 96 weeks to evaluate its antiviral effects and safety. Throughout the study, participants undergo regular safety checks including monitoring for adverse events, clinical lab tests, and pharmacokinetic assessments. For those with CHD, measurements of viral RNA levels, liver stiffness, and liver enzyme levels are taken at multiple timepoints. The study also includes follow-up periods after dosing to monitor ongoing safety and treatment responses, lasting up to 144 weeks in total for some participants.

Age: 18Years - 69YearsAll GendersPhase 1Phase 2
28 locations